In This Section
Investor Relations
Get stock updates, FAQs, and more.
Our Best-in-Class Companies
Find a powerful partner that promises results.
Contact Information
If you are representing a media outlet and have immediate questions, please contact:
MARCIA FREDERICK
614.543.6281
mfrederick@inventivhealth.com
Press Releases
inVentiv Clinical Expands Operations to Emerging Latin American Region
SOMERSET, N.J., March 13 inVentiv Clinical Solutions, LLC (inVentiv Clinical), a division of inVentiv Health (Nasdaq: VTIV - News), announced today that they will establish operations in Latin America, a growing region for drug development. The new location will be based in Sao Paulo, Brazil, with the plan to expand operations to other Latin American countries. inVentiv Clinical's Latin American operations will be led by Ana Paula Ruenis, PhD, recently appointed as Director of Clinical Operations, Latin America. Dr. Ruenis is responsible for oversight of project management and monitoring of all Latin American investigative sites for studies conducted by inVentiv Clinical.
Prior to joining inVentiv Clinical, Dr. Ruenis spent more than eight years in clinical research, representing top US pharmaceutical clients in South America, managing trials in various phases and therapeutic areas from protocol design to site and patient recruitment to final report submission. Dr. Ruenis received both her master's degree and PhD in Pharmacology from the State University of Campinas in Piracicaba, SP, Brazil. She also received training at the Biopharmaceutical Sciences Department of the University of California in San Francisco, CA.
"Having already established full off-shore operations in India, the expansion of our clinical operations into Latin America is an important next step in our goals to become a global clinical services provider," said Mike Hlinak, President and CEO of inVentiv Clinical. He added, "Dr. Ruenis has the expertise and skill to help us build our presence in South America to continue to provide superior quality services to our clients."
About inVentiv Clinical Solutions
inVentiv Clinical Solutions is the premier provider of unique clinical outsourcing solutions, allowing the greatest control and flexibility through unmatched access to high quality clinical resources. As a strategic partner, inVentiv Clinical Solutions provides clinical trial management and monitoring, data management and biostatistics solutions, medical writing, regulatory consulting and liaison services and patient and investigator recruitment. These services are complemented by traditional clinical staffing capabilities through our industry leading staffing divisions, MedFocus and Smith Hanley Consulting Group. For more information, visit www.inventivclinical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing; and our inability to determine the actual time at which the liquidation of the Columbia Strategic Cash Portfolio will be completed or the total losses that we will actually realize from that investment vehicle. . Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
